Company: CDT
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022373
Chunk: 46

Company: CDT Equity Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 46
---
 evolution of our strategy as
a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through
scientific innovation and strategic partnerships.

CDT
Equity is a data-driven biotech development and digital asset treasury management company focused on identifying, enhancing, and advancing
high-potential therapeutic assets through scientific innovation and strategic partnerships. The Company has evolved into a broader, more
agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development
of novel therapeutic treatments.

CDT
Equity’s strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by
larger pharmaceutical companies with strong, supporting Phase I safety data. Through advanced co-crystallization and solid-form technologies
developed at our Cambridge facility, we aim to improve drug properties and have successfully extended the patent life of certain drugs
by up to 20 years.

Our
current pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology,
and animal health. The intellectual property portfolio comprises pending patent applications in several international jurisdictions describing
a solid-form compound, including the AZD1656 Cocrystal (a HK-4 Glucokinase Activator). Our pipeline research includes a number of compounds
that serve as promising alternatives to existing clinical assets currently marketed and sold by large pharmaceutical companies, which
we have identified as potential opportunities to develop further intellectual property positions through solid-form technology.

Our
collaboration with Sarborg enables us to apply proprietary algorithms utilizing AI-powered disease mapping to identify novel
re-purposing opportunities across a database of more than 800 disease signatures. Sarborg’s insights have directly informed
two new combination patent filings, strengthening our intellectual property portfolio. In addition, CDT Equity has initiated
pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention. We will seek an exit
through third-party license deals following successful in vitro and in vivo pre-clinical trials, entering into agreements with third
parties to pursue further development, FDA approval, commercialization, and marketing of our assets. We continue to evaluate novel
artificial intelligence and cybernetics approaches to drug re-purposing, intellectual property, and asset selection to give CDT a
competitive advantage.

27

The
Sarborg Agreement entered into between the Company and Sarborg on December 12, 2024 is designed